Background/Aims: Melanoma antigen A6 (MAGEA6) is a cancer-specific ubiquitin ligase of AMP-activated protein kinase (AMPK). The current study tested MAGEA6 expression and potential function in renal cell carcinoma (RCC). Methods: MAGEA6 and AMPK expression in human RCC tissues and RCC cells were tested by Western blotting assay and qRT-PCR assay. shRNA method was applied to knockdown MAGEA6 in human RCC cells. Cell survival and proliferation were tested by MTT assay and BrdU ELISA assay, respectively. Cell apoptosis was tested by the TUNEL assay and single strand DNA ELISA assay. The 786-O xenograft in nude mouse model was established to test RCC cell growth in vivo. Results: MAGEA6 is specifically expressed in RCC tissues as well as in the established (786-O and A498) and primary human RCC cells. MAGEA6 expression is correlated with AMPKα1 downregulation in RCC tissues and cells. It is not detected in normal renal tissues nor in the HK-2 renal epithelial cells. MAGEA6 knockdown by targeted-shRNA induced AMPK stabilization and activation, which led to mTOR complex 1 (mTORC1) in-activation and RCC cell death/apoptosis. AMPK inhibition, by AMPKα1 shRNA or the dominant negative AMPKα1 (T172A), almost reversed MAGEA6 knockdowninduced RCC cell apoptosis. Conversely, expression of the constitutive-active AMPKα1 (T172D) mimicked the actions by MAGEA6 shRNA. In vivo, MAGEA6 shRNA-bearing 786-O tumors grew significantly slower in nude mice than the control tumors. AMPKα1 stabilization and activation as well as mTORC1 in-activation were detected in MAGEA6 shRNA tumor tissues. Conclusion: MAGEA6 knockdown inhibits human RCC cells via activating AMPK signaling.
Introduction
Renal cell carcinoma (RCC) is a main threat to human health [1] [2] [3] [4] . It is one of the most common malignancy, which causes large cancer-associated mortalities each year [5, MAGEA6 short hairpin RNA (shRNA) Two shRNAs, targeting non-overlapping sequences of human MAGEA6 cDNA, were designed and provided by Dr. Qing-Fang Sun at Shanghai Jiao-Tong University School of Medicine. The MAGEA6 shRNA sequences (Seq-a: 5'-CCGGCATTGAAACCAGCTATGTGAACTCGAGTTCACATAGCTGGTTTCAATGTTTTTTG-3'/ Seq-b: 5'-CCGGGCCCATTCTTCACTCTTTGAACTCGAGTTCAAAGAGTGAAGAATGGGCTTTTTTG-3') were based on previous study [34] . The shRNA was then inserted into the GV428 expression vector, with a Flag tag and a puromycin resistance gene. The shRNA vector was transfected to HEK-293 cells, along with plasmids of viral packaging proteins VSVG (Promega) and Hit-60 (Promega) [44] . After 48 hours, MAGEA6 shRNA virus particles were formed in the HEK-293 cell medium, which were added to RCC cells for designated time. When necessary, puromycin (5.0 μg/mL) was also added to select stable cells, which lasted for 12 days. Control cells were infected with the lentiviral scramble-control shRNA (Genepharm, Shanghai, China).
Methylthiazol tetrazolium (MTT) assay
Cell survival was tested by the routine MTT (Sigma) assay according to the manufactory's recommendations [40] [41] [42] . MTT OD at 590 nm was recorded.
Clonogenicity assay RCC 786-O cells, seeded at 1×10
4 per 10-cm culture dish, were plated in 1% agarose-containing complete medium. The complete medium was renewed every 2 days. After incubation for 10 days, the survival 786-O colonies were manually counted.
In vitro proliferation assay
Cell proliferation was tested by the BrdU ELISA assay, the protocol was described in detail in our previous studies [44, 45] . The value of treatment group was always normalized to that of the untreated control group.
TUNEL assay
The terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay allows quick and convenient detection of cell apoptosis. As described in our previous study [45] , TUNEL In Situ Cell Death Detection Kit (Roche, Shanghai, China) was applied to determine the apoptotic nuclei. TUNEL ratio of 200 nuclei (Hoechst staining) per treatment in five random views (1:100) was recorded.
Single strand DNA (ssDNA) ELISA assay of apoptosis
The production of ssDNA is a characteristic marker of cell apoptosis. ssDNA enzyme-linked immunosorbent assay (ELISA) kit was utilized to quantify DNA fragmentation from 30 μg cell lysates of each condition, via the commercial available photometric sandwich immunoassay of cytoplasmic ssDNA fragments (Roche, Shanghai, China).
Western blotting assay
Equal amount of protein lysates (30 μg per sample) were separated by 7.5-12% SDS-PAGE gel, which were transferred onto the PVDF (polyvinylidene difluoride) membranes (Millipore, Suzhou, China). After block in 10% milk, the blots were incubated with applied primary and secondary antibodies. Interested proteins were visualized via the enhanced chemiluminescence (ECL) reagents (Pierce, Suzhou, China) plus x-ray film development. Bands were always quantified through ImageJ software, and the value was normalized to the loading control.
Real-time PCR
Total RNA of RCC cells was extracted via the SV RNA isolation kit (Promega). The reverse transcription was performed using the TOYOBO ReverTra Ace-a RT-PCR kit (TOYOBO, Japan) [42] . cDNA was then mixed with SYBR Green PCR Master Mix. The real-time quantitative PCR ("RT-qPCR") was performed by the ABI- Ct method was applied to quantify mRNA expression change. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was always tested as the internal control. The mRNA primers for human AMPKα1 were described previously [34] , and were provided by Dr. Sun at Shanghai Jiao-tong University. mRNA primers for MAGEA6, forward: 5'-TGGAGGACCAGAGGCCCCC-3' and reverse: 5'-CAGGATGATTATCAGGAAGCCTGT-3' were based on previous studies [46, 47] .
AMPKα1 knockdown RCC cells were cultured in the basic medium (no FBS, no antibiotics) at 50% confluence. The lentiviral AMPKα1 shRNA (pSuper-GFP, with puromycin resistance gene), a gift from Dr. Lu [22] , was added directly to the cultured RCC cells for 24 hours. Puromycin (2.5 μg/mL) was then added to select stable cells for 10-12 days. AMPKα1 knockdown in the stable cells was verified by Western blotting assay.
AMPKα1 mutation
The dominant negative mutant of AMPK-α1 (AMPK-α1-T172A-flag, "dn-AMPK-α1-flag"), created by mutating the Thr172 residue into Ala [48, 49] , was provided by Dr. Wang [50] . The plasmid encoding a constitutively-active mutant of AMPKα1 (T172D, Ad-ca-AMPKα1-puromycin) and the empty vector (Ad) were also provided by Dr. Wang [50] . RCC cells were cultured in basic medium at 50% confluence. The construct (0.25 μg/ml) was transfected to RCC cells by Lipofectamine 2000 [51] . Puromycin (2.5 μg/mL) was added to select stable cells for 10-12 days. Expression of exogenous AMPKα1 was verified again by Western blotting assay.
Tumor xenograft assay
The female nude mice, 5-6 week age, 18.2-19.1 grams, were purchased from the Animal Center of Wenzhou Medical University (Wenzhou, China). Mice were maintained at standard conditions. For each mouse, six millions of stable 786-O cells, with MAGEA6 shRNA or control shRNA, were inoculated via s.c. injection to the right flank. Within 2-3 weeks, xenograft tumors were established, and tumor volumes were around 0.1 cm 3 . Tumor volume was measured once every 5 days for a total of 35 days using the described formula [45] . Mice body weights were also recorded. The animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of authors institutions and complied with the National Institutes of Health guide for the care and use of Laboratory animals.
Statistical analysis
Results were compared by one-way analysis of variance (ANOVA) followed by Turkey's test. Values of p < 0.05 were considered as statistically significant.
Results

MAGEA6 expression in RCC tissues and cells
First, expression of the AMPK ubiquitin ligase, MAGEA3 and MAGEA6 [39] were tested in human RCC tissues. Western blotting assay results in Fig. 1A demonstrate that MAGEA6 is specifically expressed in all four RCC tumor tissues, but is absent in the surrounding normal renal tissues. MAGEA3, a very similar protein of MAGEA6 [39] , is however quite low in both tumor tissues and surrounding normal tissues (Fig. 1A) . MAGEA6 expression in RCC tissues is correlated with AMPKα1 downregulation (Fig. 1A) . AMPKα1 protein level is clearly lower in the tumor tissues than that in the renal tissues (Fig. 1A) . p-ACC level, reflecting AMPK activity, is also high in renal tissues, but is low in the tumor tissues (Fig. 1A) . Total ACC expression is equivalent between the two sets of tissues (Fig. 1A) . The qRT-PCR assay results in Fig. 1B demonstrate that MAGEA6 mRNA expression is detected in the four RCC tissues, but it is absent in the surrounding normal renal tissues ( Fig. 1B) .
Furthermore, MAGEA6 is expressed in both established RCC cell lines (786-O and A498) and primary human RCC cells (two lines, "RCC1" and "RCC2", see Methods) (Fig. 1C) .
It is yet not detected in the HK-2 renal epithelial cells (Fig. 1C) . MAGEA3 protein expression level in RCC cells is low (Fig. 1C) 1D) . It is not detected in the HK-2 cells (Fig. 1D) . Further, the specificity of the MAGEA6 mRNA qRT-PCR assay is confirmed by testing the MAGEA6-negative (HCC1143) and MAGEA6-postive (HCC1806) breast cancer cells [34] (Fig. 1D ).
We also tested MAGEA6 expression in other eight RCC tissues ("T1-T8") with no adjacent normal renal tissues. Western blotting assay results in Fig. 1E demonstrate that MAGEA6 is expressed in three ("T5/6/7") out of the eight RCC tumor tissues. It's expression, as expected, is high in the human testis tissue (Fig. 1E , serving as the positive control). The qRT-PCR assay results in Fig. 1F confirmed MA-GEA6 mRNA expression in the three RCC tissues ("T5/6/7") and in the testis tissue, but not in other five RCC tissues ("T1-4" and "T8"). MAGEA3 is not detected in the RCC tumor tissues, but it is present in the testis tissue (Fig. 1E ). AMPKα1 expression is again low in MAGEA6-postive RCC tissues ("T5/6/7"), but it is relatively high in the MAGEA6-negative RCC tissues (Fig. 1E) . Together, these results demonstrate specific expression of MAGEA6 in RCC tissues and cells, which is correlated with AMPKα1 downregulation.
MAGEA6 shRNA stabilizes and activates AMPK in RCC cells
Above results show that MAGEA6 is expressed in RCC cells. Next, we utilized shRNA lentivirus to knockdown MAGEA6 in 786-O RCC cells. A set of two lentiviral MAGEA6 A total of eight human RCC tumor tissues ("T1-T8", no surrounding normal renal tissues) and the human testis tissue ("Testis" as the positive control) were subjected to Western blotting assay (E) and qRT-PCR assay (F) of MAGEA6 and other listed genes mentioned in the text. T1  T2  T3  T4  T5  T6  T7  T8  Testis MAGEA6 mRNA (vs. GAPDH)
E.
F. MAGEA3   T1  T2  T3  T4  T5  T6  T7  T8  Testis Tumor tissues (Fig. 2B) , but its mRNA level was unchanged (Fig. 2C) . These results imply that knockdown of MAGEA6, the AMPK ubiquitin ligase [34, 39] , induces AMPKα1 protein stabilization. Further, in the MAGEA6-silenced 786-O cells, AMPK activation, evidenced by phosphorylation (p-) of the AMPK's major downstream substrate acetyl-CoA carboxylase (ACC, at Ser-79) [52] , was increased (Fig. 2D) . Consequently, p-p70S6K1 ("p-S6K1"), the indicator of mTORC1 activation [53] , was inhibited (Fig. 2D) . The similar results were also obtained in another established human RCC cell line: A498. Infection of lentiviral MAGEA6 shRNA induced MAGEA6 downregulation ( Fig. 2E and F) , AMPKα1 protein stabilization ( Fig. 2F and G) and activation (Fig. 2H) , as well as p-S6K1 inhibition (Fig. 2H) . Notably, the scramble control shRNA ("shSCR") had no significant effects in the RCC cells ( Fig. 2A-H) . These results together indicate that MAGEA6 shRNA stabilizes and activates AMPK in established RCC cells.
MAGEA6 shRNA inhibits survival and proliferation of RCC cells, provokes cell apoptosis
Activation of AMPK can inhibit cancer cells via a variety of mechanisms [34, 39] . MAGEA6 shRNA stabilized and activated AMPK in established RCC cells (Fig. 2) , we therefore tested functional change in these cells. Results in Fig. 3A show that infection of the MAGEA6-shRNA lentivirus in 786-O RCC cells induced significant viability ("MTT OD") reduction. The number of viable 786-O colonies was also decreased (Fig. 3B) . BrdU incorporation, the indicator of cell proliferation, was also reduced by each of the lentiviral MAGEA6 shRNA (Fig. 3C) . Results from two independent apoptosis assays, including the TUNEL assay (Fig. 3D ) and ssDNA ELISA assay (Fig. 3E) , confirmed significant apoptosis activation in MAGEA6-silenced 786-O cells. These results suggest that shRNA-mediated knockdown of MAGEA6 inhibits 786-O cell survival and proliferation, activates cell apoptosis. The similar results were also observed in A498 cells. MTT assay results show that A498 cell viability was significantly decreased after infection the MAGEA6 shRNA. The scramble control shRNA ("shSCR") again had no significant effects (Fig. 3A-F) .
MAGEA6 shRNA activates AMPK signaling and kills primary human RCC cells
The results from the established RCC cells demonstrate that MAGEA6 shRNA activates AMPK signaling and inhibits cell survival and proliferation. We next tested this hypothesis in the primary human RCC cells. As described, two lines of primary human RCC cells, "RCC1" and "RCC2", were established. Both have high MAGEA6 expression (Fig. 1) . The primary cancer cells were infected with lentiviral MAGEA6 shRNA ("Seq-a") or the scramble control shRNA ("shSCR"). As shown in Fig. 4A ("RCC1") and Fig. 4B ("RCC2") , MAGEA6 shRNA induced AMPK stabilization and activation (p-ACC level increase), as well as p-S6K1 inhibition in the primary cancer cells. Consequently, cell survival was decreased (Fig. 4C) , and cell apoptosis was induced (Fig. 4D) . These results indicate that MAGEA6 shRNA activates AMPK signaling and kills the primary human RCC cells.
Activation of AMPK is required for MAGEA6 shRNA-induced RCC cell death/apoptosis
We test if activation of AMPK is required for MAGEA6 shRNA-induced RCC cell death/ apoptosis. Since the pharmacological AMPK inhibitor Compound C is toxic to the RCC cells (also described in other reports [54, 55] ), genetic strategies were applied. RCC 786-O cells were transfected with AMPKα1 shRNA (from Dr. Lu [22] ) or the dominant negative AMPKα1 ("dnAMPKα1", T172A, from Dr. Wang [50] ). Via puromycin selection, stable 786-O cells were established. Western blotting assay results in Fig. 5A confirmed AMPKα1 silence in cells with the AMPKα1 shRNA. Expression of exogenous dnAMPKα1 (Flag-tagged) was also (Fig. 5B) . Conversely, mTORC1 activation, reflected again by p-S6K1, was restored (Fig. 5B) . Importantly, MAGEA6 shRNA-induced cell death (MTT OD reduction, Fig. 5C ) and apoptosis (Fig. 5D) were significantly attenuated in 786-O cells expressing AMPKα1 shRNA or dnAMPKα1. These results imply that activation of AMPK is required for MAGEA6 shRNA-induced 786-O cell death/apoptosis. Based on the above results, we would speculate that MAGEA6 shRNA should be ineffective in the AMPK pre-activated cells. To test this hypothesis, the constitutiveactive AMPKα1 ("caAMPKα1", T172D, also from Dr. Wang [50] ) was transfected to 786-O cells. Stable cells were again established via puromycin selection. As demonstrated, caAMPKα1-expresssing 786-O cells had highlevel of basal AMPK activation (p-ACC) (Fig.  5E) . Adding the MAGEA6 shRNA ("Seq-a") lentivirus failed to further increase p-ACC (Fig. 5E) . Significantly, caAMPKα1 transfection in 786-O cells decreased cell survival (Fig.  5F ) and increased cell apoptosis (Fig. 5G) . Significantly, MAGEA6 shRNA("Seq-a") lentivirus failed to further inhibit 786-O cells with the caAMPKα1 (Fig. 5F and G) . Thus, MAGEA6 shRNA is invalid in the AMPK preactivated (by caAMPKα1) cells. These results further support that activation of AMPK is required for MAGEA6 shRNA-induced RCC cell death/apoptosis.
MAGEA6 shRNA inhibits 786-O tumor growth in vivo
At last, the nude mice xenograft model was applied. 786-O cells were infected with MAGEA6 shRNA ("Seq-a/b") lentivirus and puromycin was applied to establish the stable cells. Cells were then inoculated via s.c. injection to the flanks of the nude mice. Within 2-3 weeks when the 786-O tumor volume was around 100 mm 3 , recordings were started. Tumor growth curve results in Fig. 6A show that MAGEA6 shRNA-bearing 786-O tumors grew much slower than the shSCR-shRNAbearing control tumors. The volume of MAGEA6 shRNA tumors was much lower than that of control tumors (Fig. 6A) . At the termination of experiment (Day-35), the weight of MAGEA6 shRNA tumors was also significantly lighter than the control tumors (Fig. 6B) . The weight of 
animals was however generally indifferent between the groups (Fig. 6C) . Signaling change in vivo was also tested by analyzing fresh tumor tissue lysates. Results in Fig. 6D confirmed AMPKα1 stabilization and activation (p-ACC increase), as well as mTORC1 (tested by p-S6K1) inhibition in MAGEA6 shRNA tumor tissues. Notably, the similar results were observed in tumor lysate samples from both Day-10 and Day-20 (Fig. 6D) . These results clearly show that MAGEA6 shRNA inhibits 786-O tumor growth in vivo. 
Discussion
The results of this study suggest that MAGEA6 could be a novel therapeutic protein of RCC. MAGEA6 is specifically expressed in human RCC tissues and established/primary human RCC cells. It is however not detected in normal renal tissues nor renal epithelial cells. Knockdown of MAGEA6 by targeted-shRNAs induced AMPKα1 stabilization and activation, which subsequently led to RCC cell death and apoptosis. In vivo, MAGEA6 shRNAbearing 786-O tumor growth in nude mice was much slower than the control tumors. At the molecular level, we propose that MAGEA6 functions as a cancer-specific ubiquitin ligase to downregulate the tumor suppressor protein AMPK. MAGEA6 knockdown thus stabilizes and activates AMPK to inhibit RCC cells.
MAGEA6, as a ubiquitin ligase [38, 39] , might have multiple target proteins. Our results here suggest that activation of AMPK is required for MAGEA6 shRNA-induced killing of RCC cells. Introduction of AMPKα1 shRNA or the dn-AMPKα1 in 786-O cells almost completely blocked MAGEA6 shRNA-induced AMPK activation. Remarkably, the AMPK-deficient cells were also protected from MAGEA6 shRNA. MAGEA6 shRNA lentivirus was mostly invalid against AMPKα1-silenced or -mutated (dominant negative) cells, suggesting that activation of AMPK is key effector of MAGEA6 shRNA in RCC cells. On the other hand, expression of ca-AMPKα1 (T172D) in 786-O cells induced sustained AMPK activation, which then mimicked the actions of MAGEA6 shRNA and induced 786-O cell death/apoptosis. Notably, MAGEA6 shRNA was unable to further kill 786-O cells expressing ca-AMPKα1. Thus, MAGEA6 shRNA was also in-effective in cells where AMPK was pre-activated. These results confirm that activation of AMPK is required for MAGEA6 shRNA-induced inhibition of RCC cells.
AMPK-induced anti-cancer activity could be due to a number of different mechanisms. For example, activated AMPK in-activates mTORC1, the latter is key oncogenic signaling that is vital for RCC cell survival and apoptosis prevention [56] [57] [58] [59] . Following activation, AMPK directly phosphorylates and activates TSC2 (or Tuberous sclerosis protein 2, the mTORinhibitory upstream protein) to inhibit mTORC1 activation [15] . It has also been shown that activated AMPK phosphorylates and in-activate its substrate, also the mTORC1 component protein Raptor, leading to mTORC1 inactivation [60] . In the current study, we show that mTORC1 activation, evidenced by p-S6K1, was also inhibited by MAGEA6 shRNA. Such an effect was again reversed by AMPKα1 shRNA or mutation. Thus, MAGEA6 shRNA-activated AMPK inhibits mTORC1 activation in RCC cells, which could be at least one key reason of subsequent RCC cell death/apoptosis.
Besides mTORC1 inhibition, there are other mechanisms which account for AMPKmediated tumor suppression. Activated AMPK could directly associate and activate p53 to induce cell apoptosis and cell cycle arrest [17] . Further, AMPK could serve as a key upstream kinase protein to trigger autophagy, which could promote cell death [61, 62] . AMPK-mediated autophagy could be through direct mechanism (phosphorylation of Ulk1) and/or indirect mechanisms (mTORC1 inhibition) [61, 62] . Recent studies have confirmed that AMPK activation could lead to degradation of several oncogenic proteins or oncogenes [18, 19] . Further studies will be needed to explore the downstream effectors of AMPK that mediate MAGEA6 shRNA-induced inhibition of RCC cells.
In the current study, we show that MAGEA6 is expressed in a portion of (7 out of 12) human RCC tissues. One limitation, however, is that the number tested human tissue samples is low. One previous study has revealed that expression of MAGEA3/A6 is infrequent in RCC [34] . It will be therefore important to test MAGEA3/A6 expression in a large scale of human RCC tissue samples in future.
Molecularly-targeted therapy has drawn significant attention for the treatment of RCC [63] . mTORC1 inhibitors, including everolimus and other rapamycin analogs, are approved by FDA for treatment of certain RCC [57, 64] . These mTORC1 inhibitors have displayed promising clinical benefits in improving RCC survival [57, 64] . Our results demonstrate that mTORC1 activation is largely inhibited in MAGEA6-silenced cells, as the consequence of
